Company / R&D Expense
RIGEL PHARMACEUTICALS INC R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$33.3M
FY2025
5-year range
$23.4M / $65.2M
FY2021-FY2025
Trend
+42.4%
vs FY2024
Sector context
#188 of 210
Health Care
What the data says
Among 210 Health Care companies, RIGEL PHARMACEUTICALS INC is in the bottom 10% for r&d expense. R&D Expense returned to growth in FY2025 after 3 years of decline, reaching $33M.
Based on SEC 10-K filings.
$33M in FY2025 with a 5-year CAGR of -11.1%.
Improved from $25M to $33M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -17.9%
- 5-Year CAGR
- -11.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 210This company $33.3M Sector average $644.0M
▼
-94.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -11.1%, indicating a declining trend.
- In FY2025, r&d expense increased 42.4% year-over-year.
- Ranks #188 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.3M | +42.4% |
| FY2024 | $23.4M | -4.7% |
| FY2023 | $24.5M | -59.3% |
| FY2022 | $60.3M | -7.6% |
| FY2021 | $65.2M | +8.5% |
| FY2020 | $60.1M | +13.6% |
| FY2019 | $52.9M | -16.6% |
| FY2018 | $63.4M | +37.1% |
| FY2017 | $46.3M | -27.1% |
| FY2016 | $63.4M | +1.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026